The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).

MLA

Najim, Omar, et al. “The Prevalence of Estrogen Receptor-1 Mutation in Advanced Breast Cancer: The Estrogen Receptor One Study (EROS1).” Cancer Treatment and Research Communications, vol. 19, 2019, p. 100123. EBSCOhost, https://doi.org/10.1016/j.ctarc.2019.100123.

APA

Najim, O., Huizing, M., Papadimitriou, K., Trinh, X. B., Pauwels, P., Goethals, S., Zwaenepoel, K., Peterson, K., Weyler, J., Altintas, S., van Dam, P., & Tjalma, W. (2019). The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1). Cancer Treatment and Research Communications, 19, 100123. https://doi.org/10.1016/j.ctarc.2019.100123

Chicago

Najim, Omar, Manon Huizing, Konstantinos Papadimitriou, Xuan Bich Trinh, Patrick Pauwels, Sofie Goethals, Karen Zwaenepoel, et al. 2019. “The Prevalence of Estrogen Receptor-1 Mutation in Advanced Breast Cancer: The Estrogen Receptor One Study (EROS1).” Cancer Treatment and Research Communications 19: 100123. doi:10.1016/j.ctarc.2019.100123.